Role of brain natriuretic peptide in the diagnosis and management of heart failure: Current concepts

被引:6
作者
Latini, R
Masson, S
De Angelis, N
Anand, I
机构
[1] Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, I-20157 Milan, Italy
[2] Vet Affairs Med Ctr, Minneapolis, MN USA
关键词
neurohormonal activation; natriuretic peptides; adrenomedullin; prognostic markers; angiotensin-receptor blockade; val-HeFT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Progression of heart failure is related to ventricular remodeling, a process associated to neurohormonal activation. Brain natriuretic peptide (BNP), a member of the natriuretic peptide family, has recently emerged as an important neurohormone in the pathophysiology of heart failure. Methods: In this update, some of the recent advances on the role of BNP in heart failure are summarized. In particular, the role of BNP in diagnosis of heart disease, as a prognostic marker of cardiovascular events and as a possible guide to optimize heart failure therapy is discussed. Results: Recent results from 4,300 patients enrolled in the Valsartan Heart Failure Trial (Val-HeFT) confirmed that BNP is the strongest predictor of outcome in heart failure, when compared to other neurohormones and clinical markers. The current use of BNP in the screening and diagnosis of heart failure and its possible future roles are presented. Conclusion: In recent years, there has been an impressive accumulation of data supporting an important role of BNP as a diagnostic and prognostic marker of heart failure. Development of rapid, accurate and affordable diagnostic methods will allow the routine monitoring of BNP in a wide spectrum of settings, from general practice to controlled clinical trials.
引用
收藏
页码:288 / 299
页数:12
相关论文
共 105 条
[1]  
Abraham W T, 1998, J Card Fail, V4, P37, DOI 10.1016/S1071-9164(98)90506-1
[2]  
ANAND I, 1996, HEART FAILURE SCI PR
[3]   Mechanisms and management of renal dysfunction in heart failure [J].
Anand, IS ;
Chugh, SS .
CURRENT OPINION IN CARDIOLOGY, 1997, 12 (03) :251-258
[4]   Surrogate end points in heart failure [J].
Anand, IS ;
Florea, VG ;
Fisher, L .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (09) :1414-1421
[5]   EFFECT OF ATRIAL PEPTIDES ON ALDOSTERONE PRODUCTION [J].
ATARASHI, K ;
MULROW, PJ ;
FRANCOSAENZ, R .
JOURNAL OF CLINICAL INVESTIGATION, 1985, 76 (05) :1807-1811
[6]   Effects of β-blockers on neurohormonal activation in patients with congestive heart failure [J].
Baran, D ;
Horn, EM ;
Hryniewicz, K ;
Katz, SD .
DRUGS, 2000, 60 (05) :997-1016
[7]   Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure [J].
Baruch, L ;
Anand, I ;
Cohen, IS ;
Ziesche, S ;
Judd, D ;
Cohn, JN .
CIRCULATION, 1999, 99 (20) :2658-2664
[8]  
BONARJEE VVS, 1995, BRIT HEART J, V73, P511
[9]   EFFECTS OF PROPRANOLOL AND PINDOLOL ON PLASMA ANP LEVELS IN HUMANS AT REST AND DURING EXERCISE [J].
BOUISSOU, P ;
GALEN, FX ;
RICHALET, JP ;
LARTIGUE, M ;
DEVAUX, F ;
DUBRAY, C ;
ATLAN, G .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 257 (02) :R259-R264
[10]   DIFFERENTIAL REGULATION OF NATRIURETIC PEPTIDE RECEPTOR MESSENGER-RNAS DURING THE DEVELOPMENT OF CARDIAC-HYPERTROPHY IN THE RAT [J].
BROWN, LA ;
NUNEZ, DJR ;
WILKINS, MR .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :2702-2712